Sekimizu, M., Iguchi, A., Mori, T., Koga, Y., Kada, A., Saito, A. M., & Horibe, K. (2018). Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: Rationale, design and methods of BV-HLALCL study: study protocol. BMC Cancer.
Citação norma ChicagoSekimizu, Masahiro, Akihiro Iguchi, Tetsuya Mori, Yuhki Koga, Akiko Kada, Akiko M. Saito, and Keizo Horibe. "Phase I Clinical Study of Brentuximab Vedotin (SGN-35) Involving Children With Recurrent or Refractory CD30-positive Hodgkin’s Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Rationale, Design and Methods of BV-HLALCL Study: Study Protocol." BMC Cancer 2018.
MLA引文Sekimizu, Masahiro, et al. "Phase I Clinical Study of Brentuximab Vedotin (SGN-35) Involving Children With Recurrent or Refractory CD30-positive Hodgkin’s Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Rationale, Design and Methods of BV-HLALCL Study: Study Protocol." BMC Cancer 2018.